April 26, 2024

• 

[THE INVESTOR] As of Jan. 13 09:25 A.M., Hanall Biopharma increased 4.38% from yesterday, to 13,100 won (US$ 11.13). It increased 4.38% over the past month. Standard deviation for the one month period stood at 3.2% on the same period of time over one month.

Compared with industry competitors listed on the KOSPI, the monthly earnings rate of Hanall Biopharma was considerably higher than that of its peer group's and volatility for one month period was the highest.

The monthly return-on-risk, indicating the return on investment with consideration for risk, was 1.3. Though its volatility was high, the return-on-risk was good with higher return. Compared with the rest of the KOSPI industry, the return-on-risk was below the industrial mean, 3.1.

■ Earnings & Valuation

Hanall Biopharma (009420)
Earning reports for 3Q(July ~ Sept) of 2016
Revenue: 207.5 T   Down 0.0% on-quarter, up 13.3% on-year 
Operating income: -10.9 T
Net income: -5.2 T

Investor Groups (Over the past five trading days)
Institutions 4.46%, Foreigners 13.14%, Individuals 82.38%

* Other investor groups including corporations are considered as “individuals”.

By HeRo (hero@heraldcorp.com)

This article is produced by the algorithm developed by the artificial intelligence developer ThinkPool in collaboration with Herald Corp.